156 related articles for article (PubMed ID: 33906504)
1. Smo-Shh signaling activator purmorphamine ameliorates neurobehavioral, molecular, and morphological alterations in an intracerebroventricular propionic acid-induced experimental model of autism.
Rahi S; Gupta R; Sharma A; Mehan S
Hum Exp Toxicol; 2021 Nov; 40(11):1880-1898. PubMed ID: 33906504
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism in adult rats.
Sharma A; Bhalla S; Mehan S
Metab Brain Dis; 2022 Aug; 37(6):1909-1929. PubMed ID: 35687217
[TBL] [Abstract][Full Text] [Related]
3. Purmorphamine, a Smo-Shh/Gli Activator, Promotes Sonic Hedgehog-Mediated Neurogenesis and Restores Behavioural and Neurochemical Deficits in Experimental Model of Multiple Sclerosis.
Prajapati A; Mehan S; Khan Z; Chhabra S; Das Gupta G
Neurochem Res; 2024 Jun; 49(6):1556-1576. PubMed ID: 38160216
[TBL] [Abstract][Full Text] [Related]
4. Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals.
Rahi S; Mehan S
Cell Mol Neurobiol; 2022 May; 42(4):931-953. PubMed ID: 33206287
[TBL] [Abstract][Full Text] [Related]
5. Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism.
Khera R; Mehan S; Bhalla S; Kumar S; Alshammari A; Alharbi M; Sadhu SS
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164154
[TBL] [Abstract][Full Text] [Related]
6. A Smoothened receptor agonist is neuroprotective and promotes regeneration after ischemic brain injury.
Chechneva OV; Mayrhofer F; Daugherty DJ; Krishnamurty RG; Bannerman P; Pleasure DE; Deng W
Cell Death Dis; 2014 Oct; 5(10):e1481. PubMed ID: 25341035
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective Effect of α-Mangostin in the Ameliorating Propionic Acid-Induced Experimental Model of Autism in Wistar Rats.
Tiwari A; Khera R; Rahi S; Mehan S; Makeen HA; Khormi YH; Rehman MU; Khan A
Brain Sci; 2021 Feb; 11(3):. PubMed ID: 33669120
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of a Smoothened receptor agonist against postoperative cognitive dysfunction by promoting autophagy in the dentate gyrus of aged rats.
Li PJ; Guo YQ; Ding PY; Liu RB; Deng F; Feng XX; Yan WJ
Neurol Res; 2019 Oct; 41(10):867-874. PubMed ID: 31221056
[No Abstract] [Full Text] [Related]
9. Neuroprotective Effects of a Smoothened Receptor Agonist against Early Brain Injury after Experimental Subarachnoid Hemorrhage in Rats.
Hu Q; Li T; Wang L; Xie Y; Liu S; Bai X; Zhang T; Bo S; Xin D; Xue H; Li G; Wang Z
Front Cell Neurosci; 2016; 10():306. PubMed ID: 28149272
[TBL] [Abstract][Full Text] [Related]
10. Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder.
Gupta R; Mehan S; Sethi P; Prajapati A; Alshammari A; Alharbi M; Al-Mazroua HA; Narula AS
Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326298
[TBL] [Abstract][Full Text] [Related]
11. Lycopene ameliorates propionic acid-induced autism spectrum disorders by inhibiting inflammation and oxidative stress in rats.
Erten F
J Food Biochem; 2021 Oct; 45(10):e13922. PubMed ID: 34476820
[TBL] [Abstract][Full Text] [Related]
12. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
Mirza R; Sharma B
Chem Biol Interact; 2019 Sep; 311():108758. PubMed ID: 31348919
[TBL] [Abstract][Full Text] [Related]
13. Oxiracetam and Zinc Ameliorates Autism-Like Symptoms in Propionic Acid Model of Rats.
Paudel R; Raj K; Gupta YK; Singh S
Neurotox Res; 2020 Apr; 37(4):815-826. PubMed ID: 32026359
[TBL] [Abstract][Full Text] [Related]
14. Examining the non-spatial pretraining effect on a water maze spatial learning task in rats treated with multiple intracerebroventricular (ICV) infusions of propionic acid: Contributions to a rodent model of ASD.
Mepham JR; MacFabe DF; Boon FH; Foley KA; Cain DP; Ossenkopp KP
Behav Brain Res; 2021 Apr; 403():113140. PubMed ID: 33508348
[TBL] [Abstract][Full Text] [Related]
15. Lotusine ameliorates propionic acid-induced autism spectrum disorder-like behavior in mice by activating D1 dopamine receptor in medial prefrontal cortex.
Liu QQ; Mi J; Du YY; Rong Z; Qin Y; Jiang W; Li X; Yu JY; Yang L; Du XY; Yang Q; Guo YY
Phytother Res; 2024 Feb; 38(2):1089-1103. PubMed ID: 38168755
[TBL] [Abstract][Full Text] [Related]
16. Purmorphamine Attenuates Neuro-Inflammation and Synaptic Impairments After Hypoxic-Ischemic Injury in Neonatal Mice via Shh Signaling.
Liu D; Bai X; Ma W; Xin D; Chu X; Yuan H; Qiu J; Ke H; Yin S; Chen W; Wang Z
Front Pharmacol; 2020; 11():204. PubMed ID: 32194421
[TBL] [Abstract][Full Text] [Related]
17. Impaired Spatial Cognition in Adult Rats Treated with Multiple Intracerebroventricular (ICV) Infusions of the Enteric Bacterial Metabolite, Propionic Acid, and Return to Baseline After 1 Week of No Treatment: Contribution to a Rodent Model of ASD.
Mepham JR; Boon FH; Foley KA; Cain DP; MacFabe DF; Ossenkopp KP
Neurotox Res; 2019 May; 35(4):823-837. PubMed ID: 30848474
[TBL] [Abstract][Full Text] [Related]
18. Selective modulator of peroxisome proliferator-activated receptor-α protects propionic acid induced autism-like phenotypes in rats.
Mirza R; Sharma B
Life Sci; 2018 Dec; 214():106-117. PubMed ID: 30366038
[TBL] [Abstract][Full Text] [Related]
19. 4-hydroxyisoleucine mediated IGF-1/GLP-1 signalling activation prevents propionic acid-induced autism-like behavioural phenotypes and neurochemical defects in experimental rats.
Bhalla S; Mehan S
Neuropeptides; 2022 Dec; 96():102296. PubMed ID: 36307249
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological activation of the Sonic hedgehog pathway with a Smoothened small molecule agonist ameliorates the severity of alcohol-induced morphological and behavioral birth defects in a zebrafish model of fetal alcohol spectrum disorder.
Burton DF; Boa-Amponsem OM; Dixon MS; Hopkins MJ; Herbin TA; Toney S; Tarpley M; Rodriguez BV; Fish EW; Parnell SE; Cole GJ; Williams KP
J Neurosci Res; 2022 Aug; 100(8):1585-1601. PubMed ID: 35014067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
